The Australian medical community is buzzing with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for managing obesity. https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/